Compare · AZN vs IMNM
AZN vs IMNM
Side-by-side comparison of AstraZeneca PLC (AZN) and Immunome Inc. (IMNM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AZN and IMNM operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- AZN is the larger of the two at $555.04B, about 269.9x IMNM ($2.06B).
- Over the past year, AZN is down 3.5% and IMNM is up 93.1% - IMNM leads by 96.6 points.
- AZN has been more active in the news (21 items in the past 4 weeks vs 7 for IMNM).
- AZN has more recent analyst coverage (25 ratings vs 13 for IMNM).
- Company
- AstraZeneca PLC
- Immunome Inc.
- Price
- $181.73+1.64%
- $18.34+0.96%
- Market cap
- $555.04B
- $2.06B
- 1M return
- -1.50%
- -19.08%
- 1Y return
- -3.48%
- +93.11%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2026
- 2020
- News (4w)
- 21
- 7
- Recent ratings
- 25
- 13
AstraZeneca PLC
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Immunome Inc.
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.
Latest AZN
- NYSE Content Update: AstraZeneca Celebrates Largest Transfer in NYSE History
- Camizestrant Combination Delayed Time to First Progression by 55% and to Second Progression by 37% in Patients With Advanced HR-positive Breast Cancer With an Emergent ESR1 Tumor Mutation in SERENA-6 Trial
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- IMFINZI® (durvalumab) plus IMJUDO® (tremelimumab-actl) combined with lenvatinib and TACE reduced the risk of disease progression or death by 30% in embolization-eligible unresectable liver cancer in EMERALD-3 Phase III trial
- SEC Form 6-K filed by AstraZeneca PLC
- IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer
- SEC Form 25-NSE filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
Latest IMNM
- Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-1617, a Potential First-in-Class ADC, in Patients with Advanced Solid Tumors
- Director Bienaime Jean Jacques sold $203,820 worth of shares (10,500 units at $19.41) and bought $204,260 worth of shares (10,500 units at $19.45) (SEC Form 4)
- Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Immunome Announces Detailed Phase 3 RINGSIDE Data for Varegacestat in Adults with Progressing Desmoid Tumors at the 2026 ASCO Annual Meeting
- Barclays initiated coverage on Immunome with a new price target
- Immunome to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
- Director Bienaime Jean Jacques bought $103,500 worth of shares (5,000 units at $20.70), increasing direct ownership by 13% to 43,415 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Immunome Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Immunome Inc.
- SEC Form 10-Q filed by Immunome Inc.